Skip to main content
. 2018 Oct 12;59(12):2297–2307. doi: 10.1194/jlr.M085191

Fig. 8.

Fig. 8.

Tamoxifen resistance correlates with increased SphK1 and ERα36 expression in breast cancer patients. A: Expression levels of SphK1 and ERα36 in the indicated PDXs derived from ERα-positive (1–3) and -negative (4–11) breast cancer patients were determined by immunoblot analysis and quantified by densitometry. Data are expressed as relative densities normalized to GAPDH. * P ≤ 0.05. 1, HCI-03; 2, HCI-13; 3, HCI-11; 4, W2; 5, W30; 6, HCI-16; 7, HCI-10; 8, HCI-9; 9, HCI-1; 10, HCI-2; 11, UCD18. B, C: Breast cancer patient subtypes were from clinical expression information contained within TCGA datasets. B: SphK1 expression in TNBC versus other ERα-positive breast tumors. # P = 0.0001. C: Comparison of SphK1 expression in hormone therapy-sensitive and hormone therapy-resistant tumors. * P = 0.04.